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Atherosclerosis is a disease of chronic inflammation and is the leading cause of morbidity and mortality worldwide. There is a general consensus that the majority of coronary syndromes result from the rupture of unstable plaques and associated thrombotic events [1] [2] [3] . Plaque instability has been associated with disruption of the fibrous cap, an atheroprotective layer of smooth muscle α-actin (ACTA2)-positive cells that cover the atherosclerotic plaque [3] [4] [5] [6] [7] ; large numbers of cells positive for macrophage markers such as LGALS3; and the presence of a large foam cell-laden necrotic core within the plaque [2] [3] [4] 8 . Indeed, these data have been interpreted as evidence that plaques that contain a high ratio of macrophages relative to SMCs are less stable, particularly those that have a thin ACTA2 + fibrous cap that is presumed to be composed primarily of phenotypically modulated SMCs 9, 10 .
Although ACTA2 + and LGALS3 + cells are assumed to be of SMC and myeloid lineage respectively, there is extensive ambiguity about the lineal origin of cells within atherosclerotic plaques 11 . These ambiguities were originally based on in vitro studies showing that SMCs downregulate SMC markers and activate macrophage markers after cholesterol loading 12 , and that macrophages activate SMC genes after treatment with factors known to be present within lesions, including thrombin 13 . However, the most compelling evidence that SMCs and macrophages are often misidentified within human advanced coronary lesions comes from studies of cross-gender bone marrow transplant subjects. These studies have shown that >10% of ACTA2 + cells within lesions are of hematopoietic stem cell (HSC) and not SMC origin 14 . Consistent with these human data, a substantial fraction of the cells that express SMC markers (including ACTA2 but not MYH11) within lesions of Apoe −/− mice are of HSC and not SMC origin 15 .
Conversely, there is extensive evidence suggesting that many SMC-derived cells within advanced lesions of Apoe −/− mice lack detectable expression of conventional SMC markers such as ACTA2 (ref. 16) , and/or activate expression of macrophage markers 17 . Notably, in vivo studies from our laboratory showed that large numbers of ACTA2 − , myosin, heavy polypeptide 11, smooth muscle (MYH11) − , and transgelin (TAGLN) − cells within advanced lesions of Apoe −/− Western diet-fed mice retain expression of a mutant Tagln-lacZ transgene that is resistant to downregulation compared to the unmutated transgene 16 . Unfortunately, these studies are not definitive because we could not rule out the possibility that non-SMCs present within lesions may activate the mutant transgene.
Thus, despite decades of atherosclerosis research, we still do not know which cells within lesions are SMC-derived and to what extent they contribute to lesion pathogenesis. A recent SMC lineage tracing study using a Tagln-ER T2 Cre-lacZ Apoe −/− mouse model provided evidence that SMC-derived cells within advanced lesions activate some macrophage markers, including LGALS3 and CD68 (ref. 17) . Unfortunately, as highlighted in an editorial on this paper 18 , the labeling efficiency of SMCs in this study was only 11%, precluding a determination of the fraction of macrophage-like cells within lesions that are derived from SMCs or, most importantly, how these cells might contribute to lesion pathogenesis. Another recent study 19 showed that 50% of foam cells within advanced human coronary artery lesions express the SMC marker ACTA2, highlighting the magnitude of the 'SMC/macrophage misidentification problem' with respect to our understanding of human disease. However, the majority of these ACTA2 + foam cells also expressed the macrophage marker CD68 and represented 40% of all CD68 + lesional cells 19 . Given clear evidence that macrophages can activate SMC markers and, vice versa, that SMCs can activate macrophage markers, it is unclear whether these CD68 + lesional cells are derived from SMCs, macrophages, or another cell type.
In view of the major ambiguities in identifying which cells within atherosclerotic lesions are SMC-derived versus macrophage-derived, the most crucial questions are: (i) how are the phenotypic transitions of SMCs, macrophages, and other cell types regulated within lesions; (ii) what is the function of these phenotypically modulated cells; and (iii) how do these phenotypic transitions affect overall disease pathogenesis? To begin to address these questions, we generated atherosclerosis-prone Apoe −/− mice with which we could lineagetrace SMCs and study the effects of SMC-specific conditional knockout of the stem cell pluripotency gene, KLF4. We chose to study the role of KLF4 as we and others have previously shown that this transcription factor plays a key role in regulating phenotypic transitions of SMCs in vivo during development 20 and after carotid ligation injury 21 , as well as in vitro in cultured SMCs treated with platelet-derived growth factor (PDGF)-BB 22, 23 , PDGF-DD 24 or oxidized phospholipids 25 .
RESULTS

Most atherosclerotic plaque SMCs are not identified by ACTA2
SMCs are distinguished from other cell types by expression of a unique repertoire of genes including Acta2, Tagln, and Myh11. These genes are coordinately downregulated, at least in vitro, during SMC phenotypic switching such that they may be undetectable using traditional immunohistochemical staining methods 11, 26 . Therefore, to rigorously analyze the overall contributions of SMCs to lesion pathogenesis, we used a previously described 27 Myh11-CreER T2 ROSA floxed STOP eYFP Apoe −/− (SMC YFP +/+ Apoe −/− ) mouse model in which >95% of medial SMCs within large arteries were labeled with YFP (Supplementary Fig. 1a) . Because Cre excision is permanent, this SMC lineage-tracing model provides permanent YFP lineage tagging of virtually all mature (MYH11 + ) arterial SMCs that exist at the time of tamoxifen injection, allowing study of the further differentiation of these cells or of their progeny, irrespective of continued expression of Acta2, Myh11, or other SMC marker genes. To ensure the fidelity and SMC specificity of this lineage tracing model, we completed a number of further validation studies beyond those shown in our previous studies 27 . We demonstrated (i) SMCspecific YFP labeling within all tissue specimens examined, with no detectable expression of the YFP indicator gene in the absence of tamoxifen (Supplementary Figs. 1a,b and 2a) ; (ii) no detectable YFP + cells by flow cytometry within blood or bone marrow preparations ( Supplementary Fig. 2a) ; (iii) no evidence of YFP + cells within lesions of Western diet-fed mice not given tamoxifen ( Supplementary  Fig. 2b) ; (iv) no detectable YFP + cells in the blood of the mice when fed a high-fat diet for 18 weeks ( Supplementary Fig. 2c) ; and (v) YFP + labeling of approximately 60% of freshly enzymatically dissociated cells from the aorta (the ascending and descending thoracic aorta plus the abdominal aorta to the iliac bifurcation, including adventitial and intimal cells) on the basis of flow cytometric analysis (Supplementary Fig. 2d) .
We harvested brachiocephalic arteries (BCAs) from SMC YFP +/+ Apoe −/− mice that had been injected with tamoxifen between 6-8 weeks of age, after an additional 18 weeks of Western diet. BCAs were immunostained for YFP, ACTA2, and LGALS3. Confocal microscopy z-stacks of the collected tissues were acquired and analyzed to accurately profile individual cells (Fig. 1a-e) . Notably, ~82% of SMCs within atherosclerotic lesions (YFP + DAPI + cells) were ACTA2 negative ( Fig. 1a and SMCs within atherosclerotic plaques express markers of macrophages, MSCs, and myofibroblasts We found that phenotypically modulated (YFP + ) SMCs within lesions expressed markers of macrophages (LGALS3) (Fig. 1c) , MSCs (SCA1) (Fig. 1d) , and myofibroblasts (ACTA2 and PDGFβR) (Fig. 1e) Table 1 ). In addition, these analyses showed that 36% of LGALS3 + cells within advanced atherosclerotic lesions were YFP + , indicating that approximately one-third of cells that would normally be classified as macrophages in most previous studies in the field actually originated from SMCs, rather than from myeloid cells as previously assumed.
These initial studies were performed in paraffin-embedded samples to maintain the ultrastructure of the plaque and to determine the location of various SMC-derived cells within lesions. However, this technique limits the number of markers that can be simultaneously examined. To further characterize SMC-derived plaque cells, we performed flow cytometric analyses of freshly dissociated cells from the aorta, from the aortic root through the iliac bifurcation. We found that substantial numbers of SMC-derived cells expressed multiple additional macrophage and hematopoietic markers (Fig. 1f) . In particular, we identified YFP + cells that co-expressed the monocyte/ macrophage marker ITGAM (CD11b)) and the mature macrophage marker F4/80, as well as YFP + cells that co-expressed ITGAM and the dendritic cell marker ITGAX (CD11c). In addition, we found that 13% of the YFP + cells co-expressed the MSC markers SCA1 and ENG (CD105) (Fig. 1f) . When we analyzed MSC-like cells using traditional negative-gating strategies (CD45 − CD34 − CDH5 − ), we found that up to 45% of MSC-like cells within the aortas of 18-week Western diet-fed SMC YFP +/+ Apoe −/− mice were YFP + (Supplementary Fig. 3a) , although it is unclear whether all of these cells were located within lesions or whether they also contributed to npg the population of adventitial SCA1 + cells that have previously been described by several groups [28] [29] [30] [31] [32] . Gating strategies for all flow cytometry experiments were determined on the basis of fluorescence minus one (FMO) controls (Supplementary Fig. 3b,c) .
To further assess the morphological and possible functional properties of SMC-derived macrophage-like cells in vivo, we analyzed BCA lesions from SMC YFP +/+ Apoe −/− mice by transmission electron microscopy, combined with detection of YFP expression by immunogold labeling. As shown in Figure 2a and Supplementary  Figure 4 , we identified YFP + cells containing multiple large lipid vacuoles that seem to be phagocytic. However, these cells were relatively rare, possibly reflecting the low frequency of phagocytic YFP + cells at any given instant in time, the transient nature of this process, and/or technical difficulties in detecting these cells by immunoelectron microscopy. In addition, we flow-sorted SMC-derived MSC-like cells (YFP + ENG + SCA1 + ), non-SMC-derived MSC-like cells (YFP − ENG + SCA1 + ) and SMC-derived non-MSC-like cells (YFP + ENG − SCA1 − ) from 18-week Western diet-fed lineage-tracing mice to test the ability of these cell populations to differentiate into multiple lineages, including adipocytes and osteoblasts. After two passages in MSC maintenance medium, the SMC non-MSC-like cells became unhealthy in appearance and died (data not shown). The SMC-derived MSC-like cells survived but seemed to be senescent (Fig. 2b) and grew slowly (data not shown). These cells also failed to differentiate into either adipocytes (Fig. 2c,d ) or osteoblasts (data not shown) when exposed to the appropriate differentiation culture medium. In contrast, the YFP − (non-SMC-derived) MSC-like cells grew well (data not shown) and showed high-efficiency differentiation into adipocytes (Fig. 2c,d ) and osteoblasts (data not shown). These data indicate that although a subset of SMC-derived cells within atherosclerotic lesions express multiple markers of MSCs, these cells do not appear to be pluripotent and thus may not have the functional properties of MSCs.
SMCs within human atheromas express the macrophage marker CD68 To independently detect phenotypically modulated SMCs that express LGALS3 and to validate a method for detecting these cells in human lesions, we used an in situ hybridization proximity ligation assay (ISH-PLA) recently developed by our laboratory 27 . This technique permits the identification of phenotypically modulated SMCs within fixed tissues based on the detection of the histone H3K4diMe in the Myh11 promoter (PLA + ), a SMC-specific epigenetic signature that persists in cells that have no detectable expression of SMC markers 27, 33 . We first validated this method by showing that YFP + LGALS3 + SMCs within the lineage-tracing mice retained this SMC-specific epigenetic signature (Supplementary Fig. 5a ). We also showed that neither cultured RAW 264-7 mouse macrophage cells (Supplementary Fig. 5b ) nor human monocytes (Supplementary Fig. 5c ) exposed to POVPC, an oxidative product of LDL that activates monocytes/macrophages 34 , exhibited H3K4diMe in the Myh11 promoter.
To determine whether SMC transition to a macrophage-like state occurs in human lesions, we stained human coronary artery atherosclerotic lesions for CD68 and ACTA2 and performed ISH-PLA detection of MYH11 H3K4diMe. Multiple human coronary artery lesion sections from 12 human subjects were analyzed (Supplementary Fig. 5d ). In these lesions, 18% of CD68 + cells were PLA + (Fig. 3a-c) , indicating that they are of SMC origin. To further validate these findings, we performed the ISH-PLA analysis in coronary artery samples from a male who had received a cross-gender heart transplant ( Supplementary Fig. 6 ). 
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We found MYH11 H3K4diMe PLA + CD68 + cells that were Y chromosomenegative ( Fig. 3d) , consistent with the notion that these macrophage-like cells are of SMC and not hematopoietic origin. Notably, we never found MYH11 H3K4diMe PLA + cells that were Y chromosomepositive ( Fig. 3d and data not shown), demonstrating that myeloid cells do not acquire the MYH11 H3K4diMe SMC epigenetic signature in human atherosclerotic lesions.
KLF4 has a critical role in regulating SMC phenotype and plaque pathogenesis
We have previously shown that KLF4, a cell pluripotency factor 35 , is required for SMC phenotypic switching in several in vitro models 25, 36 . However, there is as yet no evidence that SMC phenotypic transitions within atherosclerotic lesions are KLF4 dependent, and, if so, what role these transitions have in lesion pathogenesis. Consistent with our hypothesis that KLF4 regulates phenotypic transitions of SMCs within atherosclerotic lesions, we observed large numbers of YFP + cells that expressed KLF4 within BCA lesions from 18-week Western diet-fed SMC YFP +/+ Apoe −/− mice ( Supplementary Fig. 7a ). To determine whether KLF4 regulates SMC phenotypic transitions and overall lesion pathogenesis, we generated SMC YFP +/+ Apoe −/− mice with SMCspecific deficiency of KLF4 (SMC YFP +/+ Klf4 ∆/∆ Apoe −/− mice) by crossing SMC YFP +/+ Apoe −/− mice with Klf4 fl/fl mice. We observed a high level of recombination of the floxed Klf4 alleles (Klf4 ∆/∆ ) tamoxifen treatment ( Supplementary Fig. 7b,c) , including what we estimate to be nearly 100% recombination within SMCs in the aorta when the data are corrected for the >40% of non-SMC DNA present in these samples, based on flow cytometric analysis of aortic cell populations ( Supplementary Fig. 2b ). Figure 4a shows representative confocal immunofluorescence images of the BCA lesions of control mice (SMC YFP +/+ Klf4 +/+ Apoe −/− ) and mice with loss of KLF4 in SMCs (SMC YFP +/+ Klf4 ∆/∆ Apoe −/− ) after being fed a Western diet for 18 weeks. SMC YFP +/+ Klf4 ∆/∆ Apoe −/− mice had a nearly 50% reduction in plaque size ( Fig. 4b) and multiple changes consistent with increased plaque stability, including a more-than-twofold increase in fibrous cap area (Fig. 4c) , an increase in the percentage of ACTA2 + cells within the fibrous cap (Fig. 4d) , and a reduced percentage of LGALS3 + cells (Fig. 4e) as compared to control SMC YFP +/+ Klf4 +/+ Apoe −/− mice. SMC lineage-tracing analyses showed that loss of KLF4 within SMCs did not result in a change in the overall number of SMCs (YFP + cells) within the lesions (Supplementary Fig. 8a ), but it had major effects on SMC phenotypic transitions. These effects included a 53% decrease in the percentage of macrophage-like SMCs (YFP + LGALS3 + /YFP + ) within a lesion (Fig. 4e) , a 70% decrease in the percentage of MSC-like SMCs (YFP + SCA1 + /YFP + ) within the medial area underlying lesions (Supplementary Fig. 8b ), but no change in the percentage of MSC-like SMCs in the lesion itself (Supplementary Fig. 8c Fig. 8d ), but no change in either the overall percentage of MSCs ( Supplementary  Fig. 8e ) or the percentage of YFP + cells (Supplementary Fig. 8f ) in SMC YFP +/+ Klf4 ∆/∆ Apoe −/− mice as compared to control SMC YFP +/+ Klf4 +/+ Apoe −/− mice. As noted above, SMC specific Klf4-knockout mice showed an increase in the percentage of ACTA2 + cells within the fibrous cap (Fig. 4d) as compared to wild-type control mice. Similarly, SMC YFP +/+ Klf4 ∆/∆ Apoe −/− mice showed an increase in the percentage of ACTA2 + cells within lesions (Fig. 4f) , but reduced proliferation of SMC-derived cells (Fig. 4g) and a marked reduction in YFP + SMC apoptosis as compared to control YFP +/+ Klf4 +/+ Apoe −/− mice (Fig. 4h) . These effects were not associated with changes in medial or luminal area (Supplementary Fig. 8g) , or in the percentage of cells that were YFP + PDGFβR + (Supplementary Fig. 8h ) or YFP + ACTA2 + (Fig. 4f) . In addition, we did not observe changes in cholesterol or triglyceride levels (Supplementary Fig. 8i ).
KLF4 modulates phenotypic transitions and functional properties of SMCs
We have previously presented evidence that Klf4 is induced in cultured SMCs by treatment with oxidized phospholipids 36 and that KLF4 suppresses expression of SMC marker genes through several mechanisms, including binding to the G/C repressor element found in most SMC marker gene promoters (including Acta2, Tagln, and Myh11) and inhibiting binding of the transcription factor SRF to CArG elements 16, 37, 38 . To determine whether similar mechanisms contribute to suppression of SMC marker gene expression within atherosclerotic lesions in vivo, we performed chromatin immunoprecipitation (ChIP) assays on chromatin extracted from the BCA regions of Apoe −/− mice carrying a transgene containing either an npg unmutated Tagln promoter driving lacZ expression, or a Tagln promoter with a mutation of the GC repressor element driving lacZ expression. We found that compared to chow-fed Apoe −/− mice, Western diet-fed Apoe −/− mice showed marked enrichment of KLF4 binding to the Acta2, Tagln, Myh11, and Cnn1 endogenous promoters (Fig. 5a) . Using the two transgenic strains described above, we showed that enhanced KLF4 binding to the Tagln promoter under Western diet conditions was dependent on the G/C repressor element (Fig. 5b) . Finally, using the ISH-PLA assay, we showed that KLF4 bound to the Tagln promoter in individual phenotypically modulated SMCs (YFP + ACTA2 − cells) within lesions of Apoe −/− mice (Fig. 5c) . Taken together, results provide compelling evidence that coordinated suppression of SMC marker gene expression is mediated by direct binding of KLF4 to the promoters of SMC marker genes.
We 21, 23 and others [39] [40] [41] [42] have shown that KLF4 can act as either a transcriptional repressor or activator, depending on the cell type and gene locus. To more fully define the repertoire of KLF4 target genes that mediate SMC phenotypic switching, we performed KLF4 ChIP-seq analysis on chromatin samples derived from BCAs isolated from SMC YFP +/+ Klf4 +/+ Apoe −/− versus SMC YFP +/+ Klf4 ∆/∆ Apoe −/− mice. This analysis required pooling of BCA samples from 16 mice per group to obtain sufficient DNA. Notably, we identified 869 KLF4 target genes that were selectively enriched in Klf4 +/+ Apoe −/− versus Klf4 ∆/∆ Apoe −/− Western diet-fed mice ( Fig. 5d and Supplementary  Table 2 ). These putative KLF4 target genes that were selectively bound by KLF4 in SMCs include the SMC marker genes Acta2 and Tagln, thereby validating the fidelity of our ChIP-seq analysis. In addition, we found evidence of enriched KLF4 binding in genes within regulatory pathways that are likely to be important in the pathogenesis of lesions, including gene families associated with phagocytosis, apoptosis, cell migration, and inflammation ( Fig. 5d and Supplementary  Table 2 ). These putative KLF4 target genes probably contributed to the beneficial effects of SMC-specific loss of KLF4 on lesion size and plaque pathogenesis. KLF4 also bound regions near Itgal (CD11a), Itgax (CD11b), Itgam (CD11c) (Fig. 5d and Supplementary Table 2) , and Arg1 (data not shown) in Klf4 +/+ but not Klf4 ∆/∆ mice. We also noted 459 KLF4 targets enriched in Klf4 ∆/∆ Apoe −/− samples as compared to Klf4 +/+ Apoe −/− samples ( Supplementary Fig. 9 and Supplementary Table 3), presumably representing KLF4 target genes in non-SMCs that were altered as a secondary consequence of the loss of KLF4 in SMCs. 
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Given our observation that SMC-specific loss of Klf4 is associated with a marked reduction in the percentage of SMC-derived macrophage-like cells in Klf4 ∆/∆ mice as compared to wild-type Klf4 +/+ control mice (Fig. 4f) , we tested whether KLF4 is required for transition of cultured SMCs to a macrophage-like state in vitro following cholesterol loading 12 . Owing to recent controversies concerning the origin and purity of SMCs cultured from mouse vessels 43, 44 , we used SMCs obtained by sorting freshly isolated YFP + aortic cells from our SMC lineage-tracing mice. Primary cultures of aortic SMCs harvested from 9-week-old tamoxifen-injected SMC YFP +/+ Apoe −/− mice that had been injected with tamoxifen between 6-8 weeks of age were >98% YFP + (Supplementary Fig. 10a ), indicating that these cultured SMCs are derived from mature differentiated SMCs in vivo and not from a stem cell source, as has been speculated 43, 44 . Cholesterol loading of cultured SMCs resulted in increased expression of Lgals3 (Fig. 6a) and Klf4 ( Supplementary  Fig. 10b ) as compared to vehicle-loaded control cells; the increase in Lgals3 expression was abolished in aortic SMCs derived from SMC YFP +/+ Klf4 ∆/∆ mice (Fig. 6a) . Cholesterol loading was also associated with increased phagocytic behavior of the cells as compared to vehicle-loaded control cells that was KLF4 dependent (Fig. 6b,c) . Finally, cholesterol loading resulted in KLF4-dependent increases in the expression of the pro-inflammatory cytokines MCP1, CXCR1, STNFR1 (Supplementary Fig. 10c-e), Lgals3 mRNA (Fig. 6a) , and the MSC markers Sca1 and Eng (Supplementary Fig. 10f,g ) as compared to vehicle-loaded control cells. In contrast, the increase in Abca1 mRNA expression caused by cholesterol loading was not KLF4 dependent (Supplementary Fig. 10h ).
Global heterozygous knockout of Klf4 alters plaque pathogenesis
Previous studies using VE-cadherin-Cre Klf4 fl/fl Apoe −/− and LysM Cre/Cre Klf4 fl/fl Apoe −/− mouse models provided evidence that KLF4 has an atheroprotective role in endothelial cells and myeloid cells, respectively; KLF4 deficiency in these strains resulted in increased lesion size and changes consistent with enhanced inflammation 41, 42 . Indeed, we confirmed the effects of myeloid-specific KLF4 deficiency by showing that LysM-Cre-dependent knockout of Klf4 was associated with increased lesion size (Supplementary Fig. 11a ) and Sudan IV lipid staining (Supplementary Fig. 11b ) in LysM Cre/Cre ROSA STOP floxed eYFP Klf4 fl/fl Apoe −/− mice. However, unlike previous studies 41, 42 , we did not observe changes in triglyceride or total cholesterol levels ( Supplementary Fig. 11c) . We also found a reduced number of lesional LGALS3 + cells derived from LysM-Cre-expressing cells in LysM Cre/Cre Klf4 ∆/∆ Apoe −/− mice as compared to wild-type control LysM Cre/Cre Klf4 +/+ Apoe −/− mice, based on YFP expression (Supplementary Fig. 11d) . However, these results are equivocal regarding the identity of the YFP+ cell types affected by KLF4 deficiency because cells other than myeloid cells, including SMCs, may express the LysM-Cre transgene. 
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Because the loss of Klf4 in SMCs had opposite effects on plaques to Klf4 loss in endothelial or myeloid cells, a key unresolved question is whether global conditional loss of Klf4 would be beneficial or detrimental. To test this, we generated tamoxifen-inducible homozygous Klf4-knockout mice (ER T -Cre + Klf4 fl/fl Apoe −/− ) and heterozygous Klf4-knockout mice (ER T -Cre + Klf4 fl//+ Apoe −/− ); the latter represent a model of partial inhibition of KLF4 across all cell types and thus mimic potential therapeutic approaches that would achieve partial suppression of KLF4. Unfortunately, conditional global homozygous Klf4 mice had to be euthanized at 8-10 weeks after Western diet feeding owing to excessive weight loss and the development of skin lesions; these effects are presumably due to the role of KLF4 in regulating the proliferation and differentiation of epithelial cells [45] [46] [47] [48] . Tamoxifen-treated ER T -Cre + Klf4 fl/+ Apoe −/− mice (ER T -Cre + Klf4 ∆/+ Apoe −/− ) demonstrated 50% recombination (the maximum possible recombination for a heterozygous floxed allele) in the aorta, liver, and colon ( Supplementary Fig. 12a,b) , but exhibited no changes in body weight, heart weight, or cholesterol and triglyceride levels when compared to tamoxifen-treated ER T -Cre − Klf4 fl/+ Apoe −/− littermate control mice (Supplementary Fig. 12c) .
Notably, mice with conditional global heterozygous Klf4 loss had similar effects with respect to atherosclerotic lesions as those observed for SMC-specific conditional Klf4 loss, including a 30% decrease in lesion size (Supplementary Fig. 13a) , and signs of increased plaque stability, namely increased ACTA2 + cap coverage ( Supplementary  Fig. 13b ) and decreased LGALS3 + area (Supplementary Fig. 13c ). In addition, conditional global heterozygous Klf4-knockout mice exhibited decreased intraplaque hemorrhage ( Supplementary  Fig. 13d ) and decreased apoptosis and cell proliferation (Supplementary Fig. 13e,f) as compared to ER T -Cre − Klf4 +/+ Apoe −/− control mice. Taken together, these results indicate that global loss of one Klf4 allele has beneficial overall effects on plaque development, leading to smaller and possibly more stable lesions.
DISCUSSION
Despite numerous reports showing that cultured SMCs downregulate the expression of SMC differentiation marker genes after exposure to environmental cues present in atherosclerotic lesions, including cholesterol 12 , POVPC 25 , PDGF-BB 49 , and interleukin (IL)-1β (ref. 50) , the field has relied almost entirely on the detection of these markers npg to ascertain whether a given cell within a lesion is a SMC. Indeed, this practice has contributed to the well-established dogma in the field that the role of SMCs within plaques is rather limited, albeit presumed to be beneficial by virtue of the role of phenotypically modulated SMCs in producing extracellular matrix and thereby contributing to fibrous cap formation. Herein we show that >80% of SMCs within BCA lesions are phenotypically modulated and thus would have been undetected by conventional techniques. These cells comprise ~30% of the total cellular composition of the lesion. Moreover, we show that phenotypically modulated SMCs transition to cells with multiple phenotypes within lesions, including cells that express markers of macrophages, MSCs, and/or myofibroblasts. Most notably, we show that these transitions are functionally important in that selective loss of Klf4 within SMCs results in reduced lesion size, increased fibrous cap thickness, and major reductions in the fraction of SMCderived macrophage-and MSC-like cells, but causes an increase in the fraction of ACTA2 + cells within the fibrous cap. In addition, we show that cholesterol loading of cultured SMCs induces KLF4-dependent activation of macrophage and MSC markers, expression of pro-inflammatory cytokines, and increased phagocytic behavior. Finally, our in vivo KLF4 ChIP-seq analyses identified >800 putative KLF4 regulated genes within SMCs, including many associated with pro-inflammatory processes. Taken together, these results provide compelling evidence that transitions in SMCs phenotype have a crucial role in lesion development, plaque composition, and stability, and suggest that therapeutic approaches aimed at promoting beneficial changes in SMC phenotype may be a viable means of treating advanced atherosclerosis. A key question is how the loss of Klf4 within SMCs results in a marked reduction in overall lesion size as well as in multiple changes consistent with increased plaque stability. Our data indicate that these effects are not due to a change in the number of SMC-derived cells within lesions. Recent studies by the Fisher laboratory 51 found that although some SMCs express macrophage markers after cholesterol loading in vitro, principal component analysis of microarray data revealed that these cells are distinctly different from classical monocytes, macrophages, and dendritic cells. Moreover, these cells have reduced phagocytic capacity 51 . Notably, we found that SMC derived MSC-like lesional cells seem to be dysfunctional. Accordingly, we postulate that the loss of Klf4 within SMCs results in phenotypic transitions that have favorable effects in inhibiting plaque pathogenesis, including the loss of SMC-derived cells with 'pro-inflammatory' macrophage-like properties, and the gain of SMC-derived cells that contribute to plaque stabilization through mechanisms and functions yet to be defined. Although it has long been postulated that SMCs within lesions have a beneficial role, as indicated in many review articles [9] [10] [11] 26, 52, 53 , our findings show that this is an oversimplification and that the effects of SMCs can vary dramatically depending on the nature of their phenotypic transitions. A critical challenge for future studies will be to identify the environmental cues within advanced atherosclerotic lesions that regulate phenotypic transitions of SMCs, as well as the other major cell types within lesions, and to determine how these might be manipulated therapeutically to reduce plaque burden and increase plaque stability.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The GEO accession number for KLF4 ChIP-seq data is GSE65812. . Using a Zeiss LSM700 confocal microscope, a series of eight z-stack images of 1 µm in thickness were acquired for further analysis. Owing to variation in cellular composition in different regions of the lesion, cells from five standardized fields (two near the shoulder, one near the fibrous cap, and two near the media), each 14,283 µm 2 in area, were counted to determine the cellular composition within each lesion. Close examination of each plane of the z-stack was conducted using Zen 2009 Light Edition Software (Zeiss) to ensure the presence of immunofluorescence staining coinciding with a single DAPI + nucleus. The region of the lesion within 30 µm of the luminal boundary, as determined using Zen 2009 Light Edition Software, was analyzed to determine the cellular composition of the lesion cap, and the area of this region was compared to the entire area of the atherosclerotic lesion to determine cap area/lesion area. Morphometric analyses of lesion size were completed using ImagePro Plus (Media Cybernetics) as described in Alexander et al. 56 . Researchers were blinded to the genotype of the animals until the end of the analysis.
Immuno-transmission electron microscopy. SMC YFP +/+ Apoe −/− mice fed a Western diet for 18 weeks were euthanized by CO 2 asphyxiation and perfusion fixed with 0.5% glutaraldehyde (Electron Microscopy Sciences 16300), 4% paraformaldehyde (Electron Microscopy Sciences 15700) in 1× PBS. Brachiocephalic arteries were isolated, frozen in liquid nitrogen, and sent to the University of Virginia Advanced Microscopy Core for processing. Grids were stained with an antibody specific to GFP (Abcam ab6673), followed by staining with a rabbit anti-goat secondary conjugated to 10-nm gold beads (Electron Microscopy Sciences 25229). Images were captured using a JEOL 1230 transmission electron microscope with an ultra-high resolution capture camera (Gatan UltraScan 1000 2k × 2k CCD digital imaging camera).
Flow cytometry. SMC YFP +/+ Apoe −/− mice were euthanized by CO 2 asphyxiation after 18 weeks of Western diet treatment. Mice were then perfused with 10 ml of PBS, and the aorta from the iliac bifurcation to the aortic root was gently cleaned of fat and fascia before removal from the animal. After removal from the animal, the heart was dissected away from the aortic root and the tissue was placed into an enzyme cocktail containing 4 U/ml Liberase TM (Roche 05401119001), 0.1 mg/ml DNase I, and 60 U/ml hyaluronidase in RPMI-1640. Once immersed in the digestion cocktail, the tissue was cut longitudinally, minced, and placed in a 37 °C incubator for 1.5 h. Cells were run through a 70-µm strainer and spun down at 500g for 5 min. Cells were resuspended in red blood cell lysis buffer (BD PharmLyse 555899) for two minutes and then inactivated using serum containing media, spun down again, and resuspended in 200 µl of 1× PBS. SMC-derived macrophage-like cells were identified using antibodies specific to F4/80 (eBioscience 17-4801), PTPRC (eBioscience 47-0451), ITGAM (eBioscience 45-0112), DAPI (Invitrogen), LGALS3 (BioLegend 125405), and ITGAX (eBioscience 25-0114). SMC-derived MSC-like cells were identified using negative gating for PTPRC (eBioscience 12-0451-82), CDH5 (eBioscience 17-1441), and CD34 (BioLegend 128611), and using positive gating for ENG (eBioscience 48-1051-82) and SCA1 (eBioscience 45-5981-82). All samples were run on a Beckman Coulter CyAn ADP LX flow cytometer equipped with 405-nm, 488-nm, and 633-nm lasers.
Human specimens. De-identified atherosclerotic coronary artery specimens from patients (n = 12) were collected during autopsy. These specimens were processed, fixed in paraformaldehyde, and paraffin-embedded blocks were cut into 5-µm sections. One coronary artery specimen was from a male patient who had received a heart from a female donor (n = 1). The Institutional Review Board at University of Virginia approved the use of all autopsy specimens.
In situ hybridization proximity ligation assay (ISH-PLA). ISH-PLA was performed as previously described 27 . Briefly, human MYH11, mouse Myh11, and mouse Tagln probes were generated by nick translation (using Nick Translation kit no. 10976776001, Roche) using biotin-14-dATP (Invitrogen). Biotin labeled probes (40 ng per slide) underwent denaturation in hybridization buffer (2× SSC, 50% high-grade formamide, 10% dextran sulfate, 1 µg of human or mouse Cot-1 DNA) for 5 min at 80 °C. First, sections were stained for ACTA2 (Sigma F3777) and CD68 (Santa Cruz sc20060 KP1 clone) or LGALS3 (Cedarlane CL8942AP) ( Fig. 3 and Supplementary Fig. 5 ) or GFP (Abcam ab6673) and ACTA2 (Sigma F3777) (Fig. 5) . Briefly, slides were de-paraffinized and rehydrated in a xylene and ethanol series. After antigen retrieval (Vector no. H-3300), sections were blocked with fish skin gelatin oil in PBS (6 grams per liter) containing 10% horse serum for 1 h at room temperature (21 °C). Slides were incubated with primary antibodies for 1 h at room temperature, followed by incubation with donkey anti-mouse antibody conjugated with Alexa Fluor 647 (4 µg/ml, Invitrogen). Slides were then dehydrated in an ethanol series and incubated in 1mM EDTA (pH 8.0) for 20 min. Then, samples were incubated with pepsin (0.5%) in buffer (0.05 M Tris, 2 mM CaCl 2 , 0.01 M EDTA, 0.01 M NaCl) at 37 °C for 20 min, as previously described 14 . The hybridization mixture containing biotin-labeled probes (mMyh11, hMYH11 or mTagln) or a 5-TAMRA-dUTP-labeled Y chromosome probe (clone RP11-88F4, Empire Genomics) was applied on the sections. Sections were then incubated at 80 °C for 5 min, followed by 16-24-h incubation at 37 °C. Hybridization was followed by multiple washes in 2× SSC, 0.1% NP-40 buffer. PLA was performed directly after ISH according to the manufacturer's instructions (Olink) and as previously described 27 . Sections were incubated combining mouse H3K4dime (5 µg/ml, clone CMA303 Millipore) and rabbit biotin (5 µg/ml, no. ab53494, Abcam) antibodies ( Fig. 3 and Supplementary Fig. 5 ) or mouse KLF4 [56CT5.1.6] (2.5 µg/ml, no. ab75486, Abcam) and rabbit biotin (5 µg/ml, no. ab53494, Abcam) antibodies (Fig. 5) overnight at 4 °C. The PLA amplification step was performed using the Duolink detection kit (emission wavelength: 555 nm). Finally, mounting medium with DAPI was used to coverslip the slides. Images were acquired with an Olympus BX41 microscope fitted with a Q imaging Retiga 2000R camera. Image acquisition was performed using Q Capture Pro software (Media Cybernetics & Q Imaging, Inc.). Settings were fixed at the beginning of both acquisition and analysis steps and were unchanged. Brightness and contrast were equally adjusted after merging. Image analysis was performed with ImageJ software. To estimate the percentage of SMC-derived
